BridgeLine Translational Partners
Strategy Built to Survive Diligence and Accelerate the Path to the Clinic
BridgeLine helps biotech companies build development programs that hold up in board meetings, in investor diligence, and in regulatory submissions. From target evaluation through IND and into early clinical development.
Complimentary | 30 minutes
Three Pillars
Strategy That Holds Up Under Real Scrutiny
Each pillar has a core engagement and its own Strategy Diagnostic entry point.
Preclinical & Nonclinical Strategy
We reverse-engineer the go/no-go gates that matter at your next raise or partnering discussion, then design the preclinical program backward from those gates. Species selection, dose rationale, endpoint design, CRO selection, and study sequencing, all scoped to produce decision-grade evidence, not just regulatory minimums. For teams with an existing plan, we pressure-test it the way we evaluated programs from the buy side at Sarepta: what's defensible, what's a gap, and what will get flagged in diligence.
Core Engagement
Preclinical Roadmap
3-5 weeks
Portfolio Strategy
Whether you have one program or five, the question is the same: is this the right bet? We evaluate targets, indications, and programs against the full picture: scientific rationale, competitive dynamics, commercial viability, and what it would actually take to get a term sheet, a partner, or an out-license. For multi-program companies, we help you decide which to advance, pause, or kill. For single-program teams, we validate that your indication is worth the next $2M of investment. Not just the best data. The best path to value.
Core Engagement
Portfolio Assessment
2-4 weeks
Investor & Partner Readiness
The cost of going into diligence unprepared is a failed deal and 6-12 months lost. We evaluate your program the way a pharma BD team or Series A lead would: the science, the market, the positioning, and the development plan. Then we close the gaps in the story, not just the data, before diligence exposes them. We also provide independent buy-side diligence for VCs and BD teams evaluating pipeline assets.
Core Engagement
Diligence Readiness Package
2-4 weeks
What Your Deliverables Look Like
Decision-grade deliverables. Ready for the boardroom and the partner evaluation.
Every deliverable is structured for immediate use. Visual timelines, budget tables, risk assessments, and executive summaries. No translation layer required.
How It Works
From First Conversation to Finished Deliverables
A structured path from where you are today to a development plan that passes investor and regulatory review.
Strategy Call
Share your program, stage, and the decisions keeping you up at night. BridgeLine assesses the situation and recommends whether to start with a Strategy Diagnostic or move directly into a core engagement. Complimentary, 30 minutes.
Strategy Diagnostic
A broad assessment across your most pressing dimension: preclinical strategy, portfolio strategy, or investor & partner readiness. Scored findings, gap analysis, and prioritized recommendations delivered in 1-2 weeks.
Core Engagement
Preclinical Roadmap (3-5 weeks), Diligence Readiness Package, Portfolio Assessment, or Integrated Engagement. Each delivers board-ready outputs with visual timelines, budget tables, risk assessments, and executive summaries.
Ongoing Support
Advisory or fractional leadership to carry the plan through execution. Strategy calls, protocol review, CRO oversight, board preparation, and senior judgment on call as your program advances through milestones.
Built by Someone Who's Been on Both Sides
We design programs to pass the same scrutiny we applied from the buy side.
Built IND-enabling programs as an operator at Spark Therapeutics (Roche) and StrideBio. Evaluated companies from the buy side at Sarepta on transactions valued up to $11B, supported by a network of subject matter experts across regulatory affairs, CMC, and commercial strategy.
Sometimes the right answer is to deprioritize a program or pivot the indication. We help you see that clearly before you spend 18 months and $5M on the wrong path.
Who BridgeLine Works With
Biotech companies building development programs from target evaluation through IND and into early clinical development, across one program or an entire pipeline.
Deep experience across leading modalities
What Clients and Colleagues Say
From leaders at Parallel Bio, Lilly, Bound Therapeutics, Sarepta Therapeutics, and Saturnus Bio.
“In my time working with Tim at Spark Therapeutics, he stood out for his ability to quickly identify what mattered most to reduce risk and keep teams focused on the highest-impact work. He translates complex data into clear priorities, crisp recommendations, and actionable next steps. He's highly collaborative and raises the quality of decision-making across functions. I would strongly recommend BridgeLine to any biotech building toward a key inflection point.”
Christopher Rilling, PhD
VP of Science, Parallel Bio
Frequently Asked Questions
How engagements work, what BridgeLine delivers, and what to expect.
The BridgeLine Brief
Strategy breakdowns, deal analysis, and drug development insights you won't find anywhere else. Written from inside the industry by someone who has built programs and evaluated companies firsthand. Plus updates when we publish new guides, tools, and resources for early-stage biotech teams.
By subscribing you agree to our Privacy Policy.
Ready to Build Strategy That Survives Real Review?
Book a complimentary Strategy Call. 30 minutes to assess your program, identify the gaps, and recommend the right starting point.
Book a Strategy CallComplimentary · 30 minutes · Confidential
info@bridgelinetranslational.com · bridgelinetranslational.com